Indivior PLC (NASDAQ:INDV) Stock Has Average Price Target of $46.40

Indivior PLC (NASDAQ:INDV) has earned an average rating of “Buy” from the six research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $46.40.

Several research analysts recently weighed in on the company. Wall Street Zen downgraded Indivior from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 31st. Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 2nd. Craig Hallum restated a “buy” rating and set a $53.00 price objective on shares of Indivior in a report on Tuesday, August 4th. Finally, Barclays increased their price objective on shares of Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a research report on Wednesday, October 28th.

Indivior Stock Performance

NASDAQ:INDV opened at $28.21 on Monday. Indivior has a fifty-two week low of $27.68 and a fifty-two week high of $42.81. The stock has a market capitalization of $3.33 billion, a P/E ratio of 7.88 and a beta of 0.84. The company’s 50-day simple moving average is $34.90 and its 200-day simple moving average is $35.62.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, October 29th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.06 by $0.26. Indivior had a net margin of 32.75% and a negative return on equity of 418.04%. The firm had revenue of $356.00 million during the quarter, compared to analyst estimates of $329.35 million. On average, research analysts forecast that Indivior will post 3.66 EPS for the current year.

Indivior Announces Dividend

The business also recently declared a special dividend, which was paid on Friday, November 6th. Shareholders of record on Friday, October 30th were paid a dividend of $8.13 per share. The ex-dividend date was Tuesday, November 3rd.

Insider Activity

In related news, CAO Woodrow D. Anderson purchased 1,500 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was acquired at an average price of $35.69 per share, with a total value of $53,535.00. Following the completion of the acquisition, the chief accounting officer owned 27,638 shares in the company, valued at approximately $986,400.22. This represents a 5.74% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.74% of the company’s stock.

Institutional Investors Weigh In On Indivior

Large investors have recently made changes to their positions in the stock. JW Asset Management LLC acquired a new position in shares of Indivior in the 3rd quarter valued at $358,000. Allworth Financial LP raised its stake in Indivior by 11,161.1% in the 3rd quarter. Allworth Financial LP now owns 52,139 shares of the company’s stock worth $1,869,000 after acquiring an additional 51,676 shares during the last quarter. Maryland State Retirement & Pension System lifted its position in Indivior by 47.7% during the 3rd quarter. Maryland State Retirement & Pension System now owns 26,192 shares of the company’s stock worth $939,000 after acquiring an additional 8,459 shares during the period. Illinois Municipal Retirement Fund lifted its position in Indivior by 1.0% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 62,933 shares of the company’s stock worth $2,256,000 after acquiring an additional 611 shares during the period. Finally, Pictet Asset Management Holding SA lifted its position in Indivior by 13.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 328,777 shares of the company’s stock worth $12,017,000 after acquiring an additional 39,319 shares during the period. 60.33% of the stock is owned by hedge funds and other institutional investors.

About Indivior

Indivior is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment.

The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs.

Indivior was formed in 2014 when Reckitt Benckiser separated its pharmaceutical business.